Director/PDMR Shareholding
M.U.T. AG
€28.70
16:30 19/04/24
National Express Group PLC
25 July 2019
NATIONAL EXPRESS GROUP PLC
("Company")
Notification of a transaction by a Persons Discharging Managerial Responsibilities ("PDMR")
The Company has been notified by Mr Matt Ashley, a PDMR of the Company, of the below transaction effected by him on 25 July 2019 in the ordinary shares of nominal value 5 pence each in the capital of the Company ("Shares") (ISIN: GB0006215205).
The transaction is a sale by Matt Ashley of certain Shares beneficially held by him to satisfy additional tax liabilities arising in connection with the vesting on 12 April 2019 of a three year performance conditioned nil cost option over 136,526 Shares under the Company's Long-Term Incentive Plan 2015 and the exercise on 16 April 2019 of such option. Following the sale, Mr Ashley has a residual shareholding which is in excess of that required under the Company's shareholding guidelines.
Name and position of PDMR | Number of beneficially held Shares sold at 436 pence per Share
| Total beneficial interest held in Shares following the transaction (including those held by persons closely associated)
| Total other interest held in Shares following the transaction under the Company's deferred bonus and long-term incentive plans |
Matt Ashley, President and CEO, North America
|
5,048 |
145,794
|
445,017
|
The Company can confirm that Matt Ashley has complied with his obligation to notify the Financial Conduct Authority of the above transaction as required under the EU Market Abuse Regulation.
- END -
National Express contact and telephone number for enquiries:
Jennifer Myram, Company Secretary
++44 (0) 207 805 3807
Notes:
Legal Entity Identifier: 213800A8IQEMY8PA5X34
Classification: 3.1 (with reference to DTR6 Annex 1R)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.